Among the procedural tools that have shaped the ongoing fight over compounded versions of semaglutide, tirzepatide, and liraglutide, one of the least visible to patients is the citizen petition, a formal mechanism built into FDA regulations that lets essentially anyone ask the agency to take, or not take, a specific action.

What a Citizen Petition Actually Is

Under FDA regulations (21 CFR 10.30), any person, company, trade group, or advocacy organization can file a citizen petition asking the agency to issue, change, or revoke a regulation or policy, or to take or refrain from taking some other action within its authority. Petitions are submitted to the FDA's public docket, where anyone can read them and file comments in response, which is part of why they've become a visible part of the public debate over compounded GLP-1 drugs rather than a purely internal regulatory process. A related category, so-called 505(q) petitions, applies specifically to petitions submitted close to a pending generic drug decision; those carry a statutory 150-day response deadline, specifically so they can't be used to indefinitely delay a generic approval.

How They've Been Used in the GLP-1 Fight

Novo Nordisk has filed citizen petitions asking the FDA to exclude its own drugs from the agency's lists of bulk drug substances eligible for pharmacy compounding. In one petition, filed in January 2025, the company asked the FDA to keep liraglutide, sold as Victoza, off a proposed compounding-eligible list, arguing there's no clinical need for compounded liraglutide and that the drug doesn't lend itself well to compounding, citing safety concerns. That followed an earlier petition the company filed in late 2024 covering semaglutide. Compounding pharmacy trade groups have pushed back on both petitions, disputing the safety claims and arguing the restrictions serve the manufacturers' commercial interests more than patient safety.

What a Petition Does and Doesn't Do

Filing a citizen petition doesn't change FDA policy by itself. It's a formal request that triggers a public comment period and, eventually, an agency response, but the FDA can grant it, deny it, or grant it in part, and can take considerably longer to respond to petitions outside the narrower 505(q) category. It's also not the same thing as the separate, more visible FDA Pharmacy Compounding Advisory Committee process covered elsewhere on this site, where outside experts vote on whether specific peptides belong on a compounding-eligible list; a citizen petition is a written argument submitted to the agency, not a vote by an advisory panel.

Why This Process Matters for Patients

Whether a given drug's bulk substance is excluded from or included on an FDA compounding list has real downstream effects on whether a compounding pharmacy can legally prepare a non-brand-name version of it, which in turn affects cost and availability for patients who rely on compounded versions. Tracking which petitions are pending, and how the FDA eventually rules on them, is one of the more reliable ways to anticipate changes in compounded GLP-1 availability before they show up as a new FDA rule or enforcement action.

The Bottom Line

A citizen petition is a formal, public regulatory tool, not a lawsuit and not a binding directive to the FDA, but it has become one of the main ways pharmaceutical manufacturers have pressed their case against GLP-1 compounding outside of litigation and the advisory committee process. Patients who compound any medication, or are considering it, benefit from understanding that the rules governing what pharmacies are legally allowed to prepare are still actively being contested through mechanisms like this one.